Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.450.1%
QQQ
717.500.2%
BTC/USD
79684.870.1951%
DIA
532.880.22%
GLD
406.530.06%
TLT
82.240.04%

Helus Pharma Inc

HELPNASDAQ
Trade with Public
Trade with Public
$12.22
0.453.82%
At close: Sep 4, 5:00 PM EST
$12.11
-0.11-0.92%
After Hours: Sep 4, 7:27 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentCompareOptionsStock Report

Helus Pharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Helus Pharma (HELP).

Price Target Range — 3 Quarters

Analyst Consensus — 4 Analysts

4Buy
Consensus RatingBuy# Analysts4Avg. Consensus PT$48Upside to Avg. PT+292.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 20, 2026TD CowenRitu BaralPT RaiseBuy$8→$62
Jul 27, 2026Wells FargoBenjamin BurnettInitiateOverweight$16
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
TD Cowen Maintains Buy on Helus Pharma, Raises Price Target to $62

TD Cowen analyst Ritu Baral maintains Helus Pharma (NASDAQ:HELP) with a Buy and raises the price target from $8 to $62.
Benzinga Newsdesk

PRO
Wells Fargo Initiates Coverage On Helus Pharma with Overweight Rating, Announces Price Target of $16

Wells Fargo analyst Benjamin Burnett initiates coverage on Helus Pharma (NASDAQ:HELP) with a Overweight rating and announces Price Target of $16.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Helus Pharma, Lowers Price Target to $70

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Helus Pharma (NASDAQ:HELP) with a Buy and lowers the price target from $95 to $70.
Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Helus Pharma, Lowers Price Target to $42

Canaccord Genuity analyst Sumant Kulkarni maintains Helus Pharma (NASDAQ:HELP) with a Buy and lowers the price target from $45 to $42.
Benzinga Newsdesk

PRO
TD Cowen Initiates Coverage On Helus Pharma with Buy Rating, Announces Price Target of $8

TD Cowen analyst Ritu Baral initiates coverage on Helus Pharma (NASDAQ:HELP) with a Buy rating and announces Price Target of $8.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Helus Pharma, Raises Price Target to $95

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Helus Pharma (NASDAQ:HELP) with a Buy and raises the price target from $55 to $95.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved